Aesthetic Doctors / Dentists Part time

Salary: Industry leading dayrate plus 50% profitshare.

Privè Advanced Facial Aesthetics is expanding its medical faculty and invites expressions of interest from all doctors and dentists with an interest in advanced aesthetic medicine and skin.

Applicants should have completed, or be undertaking, a Level 7 Diploma in Clinical Aesthetic Injectable Treatments with a JCCP-approved provider, or hold equivalent postgraduate aesthetic training and experience.

Clinical Governance and Standards

Privè operates within a robust governance framework and is:

• A member of the Cosmetic Redress Scheme

All treatments are delivered within clearly defined clinical protocols, informed consent processes, and evidence-based practice standards.

Centre of Excellence Partnership

In January 2026, Privè entered a formal partnership with The Glow Group, the UK & Eire distributor for Toskani Med / Toskani, an established international pharmaceutical skincare manufacturer, becoming the first UK Toskani Med Centre of Excellence. This partnership provides access to the full professional and homecare Toskani Med and Toskani portfolio.

Regenerative and Injectable Therapies

Privè is the first UK clinic to clinically integrate Lumicen - Synergistic Regeneration with PDRN (3%), a professional regenerative line centred on polydeoxyribonucleotide (PDRN). PDRN has been studied for its role in:

• Cellular repair and tissue regeneration


• Angiogenesis and dermal hydration

The Lumicen professional range utilises a 3% high-purity PDRN concentration, currently regarded as the highest potency available commercially. The Lumicen Boost Serum was shortlisted for the 2026 Aesthetics Awards (Innovative Product category).

Energy-Based Transdermal Delivery

Privè offers treatment protocols incorporating the TKN Mesoject Gun, a needle-free mesotherapy system using electroporation (EPM technology). This modality facilitates temporary increases in cell membrane permeability, allowing transdermal delivery of active compounds without needles, tissue trauma, or patient discomfort.

Biorevitalisation and Skin Boosters

The HA3 / TKN 3 biorevitalisation platform utilises non-crosslinked hyaluronic acid with a molecular weight of 3000 kDa, closely approximating naturally occurring dermal HA. Compared with conventional formulations, the higher molecular weight confers:

• Slower enzymatic degradation


• Enhanced water retention


• Improved tissue turgor and elasticity

Indications include: photoaged skin, dehydration, loss of elasticity, textural irregularities, and adjunctive use alongside dermal fillers.

Objective Clinical Outcomes

Instrument-based assessments using Cutometer analysis have demonstrated:

• Elasticity improvement: 66.1%

Professional Engagement

Privè offers flexible engagement models for clinicians, including part-time, with a transparent and competitive basic day rate along with a profit-share structure.

The above vacancy is for a weekend clinic and carries and industry leading dayrate with 50% profit share.

Full administrative, regulatory, and clinical support is provided.